MSD completes acquisition of Terns to increase CML pipeline
Merck & Co (MSD) has accomplished its acquisition of Terns Prescription drugs, increasing its pipeline of therapies for persistent myelogenous leukemia (CML).
Following a profitable takeover bid and subsequent merger, the businesses introduced the completion of the transaction, making Terns an entirely owned subsidiary of MSD.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra data
The U.S. Meals and Drug Administration (FDA) not too long ago granted breakthrough remedy designation to TERN-701.
The designation applies to adults with persistent part Philadelphia chromosome-positive CML with out the T315I mutation who’ve beforehand been handled with two or extra tyrosine kinase inhibitors.
This was supported by ongoing information from the Part I/II CARDINAL trial.
MSD accomplished the money tender provide by means of a subsidiary and bought all the excellent shares of Terns widespread inventory for $53 per share, with out curiosity and topic to relevant tax withholding.
The provide expired on Could 4, 2026. A complete of 100.1 million shares, or 86.36% of Terns’ excellent shares, have been validly tendered and never withdrawn.
MSD has accepted all of those shares in accordance with the phrases of the provide and can promptly pay for them accordingly.
After completion of the tender, MSD will buy all excellent Terns shares on the time of the merger.
Terns is now an entirely owned subsidiary and its shares will now not be traded on the Nasdaq International Choose Market.
The transaction shall be handled as an asset acquisition, leading to a analysis and improvement cost of $5.8 billion ($2.35 per share) throughout the reported second quarter and full 12 months 2026 outcomes.
Usually accepted accounting rules (GAAP) and non-GAAP earnings per share are anticipated to be negatively impacted by $0.12 per share in 2026 resulting from progress and financing prices for TERN-701.
TERN-701 is a novel oral investigational allosteric breakpoint cluster area::abelson murine leukemia viral oncogene homolog 1 (BCR::ABL1) tyrosine kinase inhibitor.
It binds to the ABL myristoyl pocket, with the potential to enhance therapies for CML.
Robert Davis, Chairman and CEO of Merck, stated: “The acquisition of Terns displays Merck’s continued concentrate on science-driven, value-enhancing enterprise improvement geared toward bringing significant innovation to sufferers.
“We imagine TERN-701 has the potential to grow to be a differentiated therapy choice for sure sufferers with persistent myelogenous leukemia, and we sit up for working with the Terns workforce to advance its medical improvement.”
Final month, MSD and Google Cloud fashioned a multi-year partnership, investing as much as $1 billion, to drive agentic AI enterprise transformation.
